Podcasts about O2

Alertas por tormentas en Baleares, Cataluña y Comunidad Valenciana; clases suspendidas en Alicante. España e Israel intercambian prohibiciones de entrada a políticos por el conflicto en Gaza. Se convalidan nuevos permisos de paternidad/maternidad: 17 semanas retribuidas más 2 de cuidados hasta los 8 años. El regreso a las aulas se ha visto afectado por huelgas de profesores en varias comunidades, mientras otras lo hacen con normalidad. Se mencionan anécdotas personales y ofertas de O2.

Our primary focus immediately following return of spontaneous circulation (ROSC) is aimed at ensuring adequate perfusion of the patient's vital organs and decreasing cerebral damage.Post-arrest goals for O2 saturation, ETCO2, and BP/MAP.Indications for use of an antiarrhythmic after ROSC.Determining which antiarrhythmic to use post cardiac arrest.Administration of Amiodarone or Lidocaine to control ventricular ectopy after ROSC.The use of Amiodarone post arrest if no antiarrhythmics were administered prior to obtaining ROSC.Links to other medical podcasts that cover antiarrhythmics and other ACLS-related topics are on the Pod Resource page at PassACLS.com.**American Cancer Society (ACS) Fundraiser This is the seventh year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS Fundraiser Page: http://main.acsevents.org/goto/paultaylorTHANK YOU for your support! Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

It was an interesting weekend all the way around with fight cards in Ireland and two in Mexico and we have those recaps, plus, there's plenty of fight news, including two legends that are apparently going to fight despite being some 80 lbs apart?! Yes, indeed and we'll cover it on the "Fight Freaks Unite Recap Podcast."Host T.J. Rives is back with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter to cover it all with their thoughts.First, they recap the Matchroom main event Saturday on DAZN in Los Mochis, MexicoJunior lightweight Eduardo “Sugar” Nunez decisions Christopher Diaz and retains his IBF title. TREMENDOUS FIGHT says Dan. They have more. Next, the Recap of the Zanfer Promotions main event Saturday on ESPN Deportes in Nogales, MexicJunior lightweight and former two division world champ Oscar Valdez decisions Ricky Medina, and rebounds from his KO loss to Navarrete in their title rematch. Plus, a quick recap of the Wasserman Boxing main event on Friday in Dublin, IrelandFeatherweight former title challenger Michael Conlan scores an easy TOK4 of Jack Bateson.Then, some NewsFloyd Mayweather and Mike Tyson sign for spring exhibition!! WHAT ARE WE DOING HERE!?!Queensberry formally announces Joseph Parker vs. Fabio Wardley heavyweight fight for Oct. 25 at The O2 in London on DAZN PPV. Presser on Tuesday in London. Winner is Usyk mandatory. And, Frank Warren confirms rising heavyweight star Moses Itauma will be back Dec.13 to headline at Co-op Live in Manchester, England. Opponent TBA.Eddie Hearn confirms Anthony Joshua, who is recovering from elbow surgery, won't fight the rest of this year and will likely return Jan/Feb and there is interest in him fighting in Ghana.This is wild – WBC held a purse bid on Friday for the rematch between cruiserweight titlist Badou Jack and former titlist Noel Mikaelian. Two bids and it was a tie!!! The WBC said that has never happened before. Made them bid again and Bash Promotions won!It's all part of the "Fight Freaks Unite Recap Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.!

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

It was an interesting weekend all the way around with fight cards in Ireland and two in Mexico and we have those recaps, plus, there's plenty of fight news, including two legends that are apparently going to fight despite being some 80 lbs apart?! Yes, indeed and we'll cover it on the "Fight Freaks Unite Recap Podcast."Host T.J. Rives is back with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter to cover it all with their thoughts.First, they recap the Matchroom main event Saturday on DAZN in Los Mochis, MexicoJunior lightweight Eduardo “Sugar” Nunez decisions Christopher Diaz and retains his IBF title. TREMENDOUS FIGHT says Dan. They have more. Next, the Recap of the Zanfer Promotions main event Saturday on ESPN Deportes in Nogales, MexicJunior lightweight and former two division world champ Oscar Valdez decisions Ricky Medina, and rebounds from his KO loss to Navarrete in their title rematch. Plus, a quick recap of the Wasserman Boxing main event on Friday in Dublin, IrelandFeatherweight former title challenger Michael Conlan scores an easy TOK4 of Jack Bateson.Then, some NewsFloyd Mayweather and Mike Tyson sign for spring exhibition!! WHAT ARE WE DOING HERE!?!Queensberry formally announces Joseph Parker vs. Fabio Wardley heavyweight fight for Oct. 25 at The O2 in London on DAZN PPV. Presser on Tuesday in London. Winner is Usyk mandatory. And, Frank Warren confirms rising heavyweight star Moses Itauma will be back Dec.13 to headline at Co-op Live in Manchester, England. Opponent TBA.Eddie Hearn confirms Anthony Joshua, who is recovering from elbow surgery, won't fight the rest of this year and will likely return Jan/Feb and there is interest in him fighting in Ghana.This is wild – WBC held a purse bid on Friday for the rematch between cruiserweight titlist Badou Jack and former titlist Noel Mikaelian. Two bids and it was a tie!!! The WBC said that has never happened before. Made them bid again and Bash Promotions won!It's all part of the "Fight Freaks Unite Recap Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.!

We're back after Labor Day Weekend off (and without much boxing) because two separate main events are happening in different Mexican cities Saturday. And, the WBC's top junior miiddleweight joins us too on the 'Big Fight Weekend Preview Podcast!"Host T.J. Rives returns with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter to go over it all.First, they preview Saturday's Matchroon main event in Los Mochis, Mexico on DAZNEduardo “Sugar” Nunez defends his IBF 130 lb. title vs. veteran Christopher Diaz. Is Nunez ready to rock and roll in this one in his hometown? Plus, what is waiting for him, if he does? Then, a Preview of Satuday's Zanfer card in Nogales, Mexico, on ESPN Deportes in USAOscar Valdez returns vs. Ricky Medina, 10 rounds, lightweights. Does Oscar have much left? Next it's big Dan's interview with junior middleweight contender Serhii BohachukHe risks his WBC 154 mandatory status, as he looks to avenge a 2021 TKO loss to Brandon Adams in a rematch on the upcoming Sept. 13 Canelo-Crawford undercard.Then, some NewsSuper middleweight contender Jaime Munguia will not face any disciplinary action stemming from a positive drug test related to his unanimous decision win against Bruno Surace in their rematch on May 3; ruled contamination  I'm sorry what?! Dan has more.A fight is in works between interim heavyweight titleholders Joseph Parker and Fabio Wardley for Oct. 25 at O2 in London. It's definitely a bigger risk for Parker, who stands to be elevated to full WBO champ or also get a shot a Oleksandr Usyk, Yet, he's fighting the big punching Wardley.Next, lineal/WBO junior welterweight champion Teofimo Lopez and WBC lightweight titlist Shakur Stevenson have been in talks with Turki Alalshikh and his team about a fight targeted for a Riyadh Season card in January. It isn't done, yet, and is a hang up that one or both fighters might want the bout in the U.S.There was a presser in LA on Wednesday to officially announce the October 25 "PBC on Prime Video" PPV at MGM Grand in Las Vegas:--Sebastian Fundora vs. Keith Thurman, for Fundora's WBC junior middleweight title--O'Shaquie Foster vs. Stephen Fulton, for Foster's WBC junior lightweight title--Jesus Ramos vs. Shane Mosley Jr., for vacant WBC interim middleweight title--Isaac Lucero vs. TBA, 10 rounds, junior middleweightsThe guys discuss the interesting parts of the presser and the bouts.And, finally, Juan Orengo's Fresh Productions, the promoter for WBC junior welterweight titlist Subriel Matias, won the purse bid on Tuesday for the promotional rights to his mandatory defense against Dalton Smith, so wont be on Turki Alashikh's big Nov 22 card in Riyadh.It's all part of the "Big Fight Weekend Preview Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.! 

We're back after Labor Day Weekend off (and without much boxing) because two separate main events are happening in different Mexican cities Saturday. And, the WBC's top junior miiddleweight joins us too on the 'Big Fight Weekend Preview Podcast!"Host T.J. Rives returns with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter to go over it all.First, they preview Saturday's Matchroon main event in Los Mochis, Mexico on DAZNEduardo “Sugar” Nunez defends his IBF 130 lb. title vs. veteran Christopher Diaz. Is Nunez ready to rock and roll in this one in his hometown? Plus, what is waiting for him, if he does? Then, a Preview of Satuday's Zanfer card in Nogales, Mexico, on ESPN Deportes in USAOscar Valdez returns vs. Ricky Medina, 10 rounds, lightweights. Does Oscar have much left? Next it's big Dan's interview with junior middleweight contender Serhii BohachukHe risks his WBC 154 mandatory status, as he looks to avenge a 2021 TKO loss to Brandon Adams in a rematch on the upcoming Sept. 13 Canelo-Crawford undercard.Then, some NewsSuper middleweight contender Jaime Munguia will not face any disciplinary action stemming from a positive drug test related to his unanimous decision win against Bruno Surace in their rematch on May 3; ruled contamination  I'm sorry what?! Dan has more.A fight is in works between interim heavyweight titleholders Joseph Parker and Fabio Wardley for Oct. 25 at O2 in London. It's definitely a bigger risk for Parker, who stands to be elevated to full WBO champ or also get a shot a Oleksandr Usyk, Yet, he's fighting the big punching Wardley.Next, lineal/WBO junior welterweight champion Teofimo Lopez and WBC lightweight titlist Shakur Stevenson have been in talks with Turki Alalshikh and his team about a fight targeted for a Riyadh Season card in January. It isn't done, yet, and is a hang up that one or both fighters might want the bout in the U.S.There was a presser in LA on Wednesday to officially announce the October 25 "PBC on Prime Video" PPV at MGM Grand in Las Vegas:--Sebastian Fundora vs. Keith Thurman, for Fundora's WBC junior middleweight title--O'Shaquie Foster vs. Stephen Fulton, for Foster's WBC junior lightweight title--Jesus Ramos vs. Shane Mosley Jr., for vacant WBC interim middleweight title--Isaac Lucero vs. TBA, 10 rounds, junior middleweightsThe guys discuss the interesting parts of the presser and the bouts.And, finally, Juan Orengo's Fresh Productions, the promoter for WBC junior welterweight titlist Subriel Matias, won the purse bid on Tuesday for the promotional rights to his mandatory defense against Dalton Smith, so wont be on Turki Alashikh's big Nov 22 card in Riyadh.It's all part of the "Big Fight Weekend Preview Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.! 

Idealizada por unos y negada por otros, la mafia italiana ha teñido el sur del país de sangre y corrupción durante décadas, extendiendo sus tentáculos por todo el planeta. Pocas organizaciones criminales han marcado tanto la historia de un país como las mafias italianas. Desde sus orígenes en el siglo XIX hasta convertirse en imperios transnacionales del crimen, la Cosa Nostra, la Camorra y la 'Ndrangheta han demostrado una capacidad única para adaptarse, sobrevivir y prosperar. A través de guerras internas, alianzas con el poder político y su transformación en iconos culturales, estas hermandades criminales han logrado infiltrarse en las instituciones, controlar territorios y generar miles de millones de euros anuales. Hoy en "No es el fin del mundo" hablamos de las mafias italianas. Libros mencionados: La Camorra - Marc Monnier Analyzing Mad Men. Critical essays on the television series - Scott F. Stoddart (mencionado en ejemplo anterior) El fin del trabajo - Jeremy Rifkin, Capítulo 2: Tecnología cambiante y realidades de mercado (mencionado en ejemplo anterior) Este episodio cuenta con una mención publicitaria de O2. 💟 Si te gusta este podcast, síguelo para no perderte nuestros episodios semanales. Y si puedes, ¡recomiéndanos a tus amigos, conocidos y familia! ⭐️ Pon 5 estrellitas donde escuches el podcast (dale a la campana de Spotify o YouTube, suscríbete desde iVoox, dale al "+" de arriba a la derecha de Apple Podcast...) 🌏 Y si quieres suscribirte y apoyarnos con el código PODCAST, puedes hacerlo aquí: https://elordenmundial.com/suscribete/ Learn more about your ad choices. Visit megaphone.fm/adchoices

durée : 00:00:52 - L'agence O2 de Dordogne, service à la personnes, organise un job café à Perigueux et Sarlat. - Le jeudi 4 septembre, O2 organise un Job Café à Périgueux et Sarlat. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

The Shift from Certainty to NuanceWe've all heard the saying: facts don't change minds. But new research challenges that idea.In this episode, David talks with social scientist Nick Stagnaro about what happens when people dive deep into the facts on divisive issues like gun control. The findings? Knowledge can soften extreme positions—shifting people toward a more nuanced middle ground.But here's the catch: while attitudes toward policies change, feelings toward people on the “other side” often don't. That puzzle drives Nick's research into belief change, polarization, and how credibility, trust, and even AI-driven debates might help bridge divides.Listen in to explore how facts can move us—and where they fall short.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, David9 second versionSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

Playing drums at Red Rocks or the O2 or the Greek are dreams made reality for Harry Terrell. As producer and multi-instrumentalist, he brings perspective to the drum kit, electronics to the acoustic, and vibe to the studio. In this pod, Harry shares some of his favorite techniques for getting killer drum sounds, navigating music theory, and what it means to be a modern musician. The drums are alive and well! Chef Harry T is a drummer/producer/multi-instrumentalist/songwriter/chef/tall guy based in the Los Angeles area. He likes to do lots of stuff, including play for Still Woozy, make silly funk jams, write serious love songs about personal development and feelings, push the boundaries of sandwich possibilities, learn new Spanish vocabulary, and stretch out his sore little legs. He also REALLY likes to make music with his best bud Eli Goss, who will join us in the interview at some point, in their best-friendship-band of over 10 years called The Breathing Effect, which basically makes complex-yet-familiar bangers with influences ranging from ambient noise music to 70s Japanese city pop and yacht rock to 2000s indie rock and and softcore songwriter.For 30% off your first year of DistroKid to share your music with the world click ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DistroKid.com/vip/lovemusicmore⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to this pod's blog on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Substack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to receive deeper dives on the regular

Welcome to Season Four of Road to the Trials!This will be the most epic season yet as we look to interview every qualifier to the 2028 Olympic Marathon Trials in Los Angeles as well as plenty of industry professionals along the way. Our expanded goal is matched by our expanding team! We now have three co-hosts - Matt Chittim, Lindsey Hein, and Peter Bromka.We are thrilled to be your central hub for everything related to the Olympic Marathon Trials. This season, we're diving deep into the stories, challenges, and triumphs of athletes on their journey to the Trials.Follow us on Instagram @RoadToTheTrials for behind-the-scenes content and post-race highlights as well as our new website www.roadtothetrials.com.SponsorBig shout-out to the best coaching platform in the business - V.O2. V.O2 was built from the foundation of a scientifically-validated training methodology. Based on former Olympian, author, and legendary running coach Jack Daniels' exercise science principles, the methodology not only benefits runners of all ages and abilities when it comes to improving their running fitness but it also serves as the best measure of running economy. Visit https://vdoto2.com today for more information.

Wanna send us a message? On this Episode, The Prez, Chris and Jamie discuss their Forbidden Door experience at the O2 in London, chat about the previews of WWE Topps Finest 2025, give our predictions for Clash and run through the latest sets in Topps SlamSupport the show

The boys are heading off on holiday, but with very different agendas. Sam is in full “Uncle Sam” mode, third wheeling his sister's trip with baby Leo, while Pete insists he's off to Ibiza for work. As part of his Ibiza prep, Pete tries his hand at a practice vibe check call as we put him on the spot to call up Sheesh…Meanwhile, all that nephew time has Sam feeling surprisingly broody, while Pete's focused on the O2. With the NTAs around the corner, the boys look back on last year's red-carpet drama and spill a little behind-the-scenes gossip.

Review the indications, contraindications, sizing, and insertion of the nasopharyngeal airway (NPA) to maintain the airway of patients with a gag reflex.The tongue is the most common airway obstruction in an unconscious patient.When the nasopharyngeal airway (NPA) should be used as an alternative to the oropharyngeal airway (OPA).Examples of when a NPA should be considered.Contraindications and considerations for nasal airway insertion.Measuring a nasal airway for appropriate length and diameter.Insertion of a nasopharyngeal airway into the right vs left nostril.Patients with a NPA in place can receive supplemental O2, be ventilated with a BVM, have ETCO2 monitored, and have their upper airway suctioned as needed. **American Cancer Society (ACS) Fundraiser This is the seventh year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS Fundraiser Page: http://main.acsevents.org/goto/paultaylorTHANK YOU for your support! Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

What a Forbidden Door weekend! Lucy, Andy, Brett and Wrestling Mark tell ALL their stories from a crazy week starting in Glasgow for AEW Dynamite and Collision, going through several incredible British indie shows before culminating at the big one, AEWxNJPW: Forbidden Door at the O2 in London! Dan was also there, but fell ill before we recorded.We discuss our matches of the weekend, potential heel and face turns, MJF's evolution as a character, the Don Callis Family, some surprising title changes, and much more! Get stuck right into the juicy stuff. Press play and enjoy the ride!

I tuhle epizodu podporuje projekt Digitální zdraví od O2. Přečti si o něm víc a vyzkoušej v testu, jak si na tom se svým digi zdravím stojíš ty: https://digitalnizdravi.cz

Matt Maher, aka Imp, revisits the AEW week that was.This week talking Dynamite & Collision in the Hydro in Glasgow, and Forbidden Door live from the O2 in London!Dynamite- Greg's Sausage Rolls, Will Ospreay & Jon Moxley (1:55)Collision- Scotland's Hechicero Love (10:25)Forbidden Door Review- Adam Copeland & "Heyyy, Christian, will you be my dad?" (20:54)The Social Suplex Newsletter: https://www.socialsuplex.com/frontpage-8/Chopped Tees official Imp Merchandise: https://chopped-tees.com/en-uk/collections/social-suplex-network/imps-wwe-adventure2024 FOH Draft = https://payhip.com/b/0dVQpFollow us on Bluesky: @socialsuplex.bsky.social, @thedamnimplicat.bsky.socialFollow us on Twitter: @SocialSuplexFollow us on Instagram: @SocialSuplexLike us on Facebook: https://www.facebook.com/SocialSuplex/Join our Discord: https://discord.gg/QUaJfaCVisit our website for news, columns, and podcasts: https://socialsuplex.com/Join the Social Suplex community Facebook Group: The Wrestling (Squared) CircleSupport the Social Podcast Network by leaving a rating and review on Apple Podcasts.Support this podcast at — https://redcircle.com/social-suplex-podcast-network/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Joining us this episode to discuss the highs and lows of parenting (and life) is the brilliant singer, songwriter and presenter - Olly Murs. Fresh off a sold-out Arena tour, including three massive dates in London (two at The O2 & one at Wembley Arena), Olly Murs is currently back on the road continuing his 15 Years Of Hits celebration across the UK with a run of outdoor summer shows. With seven studio albums under his belt, including five chart topping records, Olly just released his new single 'Save Me' and has an album due later in the year.  Tour dates: August 2025 Fri 29th Blackpool, Illuminations Sat 30th Jedburgh, Edge Fest    Parenting Hell is a Spotify Podcast, available everywhere every Tuesday and Friday. Please subscribe and leave a rating and review you filthy street dogs... xx If you want to get in touch with the show with any correspondence, kids intro audio clips, small business shout outs, and more.... here's how: EMAIL: Hello@lockdownparenting.co.uk Follow us on instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@parentinghell⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ A 'Keep It Light Media' Production  Sales, advertising, and general enquiries: hello@keepitlightmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

 Dr. Jeff Gross — Board-certified neurological surgeon, biochemist, biohacker, founder of Celebrate Regenerative Medicine, and longevity/biohacking consultant based in Las Vegas & Southern California. Medical & Health Longevity Background: Dr. Gross trained at UC Berkeley (Biochemistry & Molecular Biology), George Washington University School of Medicine, UC Irvine (Neurosurgery), and UNM (Spinal Biomechanics). He has decades of frontline experience in spine surgery, sports injuries, regenerative medicine, and now consults on biohacking and longevity. Biohacking & Longevity: Biohacking is essentially circles back to ancient wellness wisdom (eat well, sleep, exercise)—but enhanced by modern science (measuring phytonutrients, leveraging tech like red light, hyperbaric therapy, protein timing, etc). Emphasizes that “prevention” is still the number one defense against the four top causes of death in Western countries; early proactive screening and lifestyle habits remain critical. There is increasing crossover between “traditional medicine” and “naturopathic”/“functional” approaches—Dr. Gross sees this convergence as positive and overdue, but notes resistance still exists in mainstream medicine. Emerging Business Opportunities in the Wellness Space: IV centers, cryotherapy, and retail biohacking clinics (hyperbaric O2, red light therapy, peptides, weight loss clinics, etc.) are booming, especially in health-conscious cities. Low-barrier options: health coaching, nutrition consulting, affiliate/online influencer businesses—Dr. Gross notes people he knows personally earning seven figures as wellness affiliates. Innovations: Short-form EMS (electro-muscular stimulation) workouts, “blood flow restriction” exercise systems, and more. Cancer screening clinics: Now possible with advanced genomics and blood-testing—these are in demand but not widely available through traditional doctors/insurance, opening more avenues for direct-to-consumer providers. Supplementation & Biohacking Basics: “Non-negotiables” for almost everyone: Vitamin D3 (& often K2): Most people are deficient; optimal blood levels promote longevity, reduce inflammation, and lower all-cause mortality. Magnesium: Especially at night for recovery and cellular repair. Creatine: Improves muscle mass, heart health, and brain health; well correlated with longevity. Probiotics: Modern lifestyles make gut health challenging—good probiotic support is important. Nicotine: Can be a cognitive enhancer in low doses and proper delivery (gum/patch, NOT smoking)—but is highly addictive. Other Business/Money Ideas: Successful affiliate and influencer businesses for those passionate about health and wellness. Emphasizes supplement sales (with high trust and real value), personalized coaching, and education are evergreen opportunities. Industry Critique: Criticizes health insurance as a “legal mafia,” noting it often adds cost and hassle while limiting real preventive care. Encourages listeners to be their “own best advocate” for health—don't rely only on five-minute mainstream doctor visits. Connect with Dr. Jeff Gross: https://recellebrate.com/

The Hidden Power of Social NormsSocial media often gets blamed for fueling outrage and deepening political divides. But what if the very tools that spread division could be used to bridge it?In this episode, we talk with Kristin Hansen, Executive Director of Civic Health Project, about Normsy.ai—a groundbreaking initiative using human-plus-AI tools to foster civility and connection online.Kristin shares her personal journey into bridge-building, why social norms matter just as much as rules, and how we can all play a part in reshaping the online world for the better.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

K této epizodě nás inspiroval projekt Digitální zdraví od O2. Přečti si o něm víc a vyzkoušej v testu, jak si na tom se svým digi zdravím stojíš ty: digitalnizdravi.cz

Does Sam even exist? This week, we flip it and put Sam to the test on DIY, MegaBus, and budget flights - which somehow leads Pete to bring up a story about Sam's in-flight tummy troubles.The bedazzled eye patch has officially joined Pete's wardrobe, and we've got BIG NEWS about the O2… more tickets have just dropped!Oh, and after all your requests, we can finally reveal the O2 dress code. Clue: think shits and penises.

What Happens When Students Talk Across Generations?We sit down with with Dr. June Klees, a historian and educator at Bay College, about the Waging Dialogue initiative — a unique civics program designed to help students develop the confidence and skills to engage in dialogue across generational and ideological divides. Students are paired with older conversation partners in what's called an “intergenerational dyad,” encouraging sustained, intentional conversations that challenge assumptions, stretch comfort zones, and build common ground.You'll also hear directly from students reflecting on their personal experiences, growth, and takeaways from the program.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

Bryce and Omari Sankofa II (O2) welcome on to the pod Omari’s dad, the original Omari Sankofa (O1). The guys get the fan perspective from Mr. Sankofa on topics like why the team should run its roster back and Jaden Ivey's x-factor. The trio also field listener questions, including how O2 started his journalism career. Later in the show, producer Wes pits father against son and co-host against co-host in another round of “Sheed or Sham”. Follow Omari on Twitter: @omarisankofa Read the latest from Omari on freep.com Follow Bryce on Twitter: @MotorCityHoops Read the latest from Bryce on substack Pick up "The Pistons Pulse" merch here!

It's a skeleton crew this week — Andy's allegedly hiding out in the Canary Islands (probably dodging Konnan), so it's just Dan, Brett, and Lucy steering this runaway train.Karrion Kross and Scarlett's contracts might be expiring… or it might be a work… or maybe it's just a distraction while WWE sleepwalks through another PR nightmare. Either way, people online make it out to be the Da Vinci Code, and we're here to poke holes in the hype.From there, we're jumping straight into the good stuff: AEW might be on its hottest run in years. Collision and Dynamite are firing on all cylinders, Forbidden Door is around the corner, and we could be seeing Nigel McGuinness in the O2. Plus, your Discord and Twitter questions take us from fantasy booking chaos to arguing about trios titles, women's tag divisions, Mercedes Mone, and everything in between.It's opinionated, unfiltered, and sometimes a bit messy — exactly how wrestling podcasting should be.Timestamps00:00 Introduction and Overview of Karrion Kross and Scarlett's Situation00:00 The Hype Around Karrion Kross: A Mystery Unveiled03:22 WWE vs AEW: The Fan Dynamics and Booking Strategies06:13 The Impact of AI on WWE's Production and Creative Choices09:02 The Nexus and John Cena: A Look Back at Wrestling History12:09 AEW's Current Success and Fan Engagement15:13 Ratings and Audience Curiosity: The Shift Towards AEW18:10 Conclusion: The Future of Wrestling and Fan Expectations25:16 Wrestling Predictions and Speculations28:14 Taking the Piss Out of Ratings and Audience Engagement31:17 Streaming Services and Pay-Per-View Dynamics34:18 Trios Titles vs. Women's Tag Titles49:12 Future of Women's Tag Team Wrestling52:08 Crowning the Best: Women's Tag Team Champions55:21 Character Development: Mercedes and Harley Cameron58:27 Building Feuds: Athena and Mercedes01:04:23 Forbidden Door: Ospreay's Potential Matches01:09:33 Zack Sabre Jr. and the Future of British Wrestling

No episódio de hoje do Check-up Semanal, confira as últimas notícias sobre: Uso de cannabis e ansiedade; O2 (máscara) vs VNI pré tubo; histoplasmose e imunossupressão; dieta cetogênica na obesidade e miocardiopatia induzida por arritimia. Ouça agora!Confira esse e outros posts no ⁠Portal Afya⁠ e siga nossas redes sociais!⁠Facebook⁠⁠Instagram⁠⁠Linkedin⁠⁠Twitter

The Connection Opportunity Report: Hope, Barriers, and the Path ForwardHow can we truly connect across political, racial, religious, and class divides? In this episode of Outrage Overload, host David Beckemeyer dives into the Connection Opportunity report from More in Common with guests Kate Carney and Calista Small.Discover:✅ Why most Americans still want connection—even across differences✅ The biggest barriers keeping us apart✅ How working together locally can overcome political tensions ✅ Digital tools and organizations fostering healthy dialogue ✅ Practical steps anyone can take to help build a culture of connectionKate and Calista share surprising insights from one of the most comprehensive studies on social cohesion and offer hope and actionable ideas for bridging divides in our communities.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

Hypoxia is a state of low oxygen levels in the blood.Determining hypoxia using a pulse oximeter or arterial blood gasses (ABGs).A goal of ACLS is to recognize signs of hypoxia and provide timely treatment to prevent an arrest.Examples of some things that might lead us to think of hypoxia as a cause of cardiac arrest.Why we should not rely on pulse ox to give accurate readings during CPR.Delivering ventilations with near 100% oxygen concentration using a BVM attached to supplemental O2 and a reservoir.Using end tidal waveform capnography to assess the quality of CPR.Changes to ventilation rates, tidal volume, and O2 concentration affects a patient's oxygen, carbon dioxide, and pH. The danger of excessive ventilation of a patient in cardiac arrest.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Mobilní síť O2 se dopoledne potýkala s masivními výpadky. Jak odolná je infrastruktura mobilních síti v takových případech? Jaké finanční ztráty představuje pro stát nelegální zaměstnávání a jaké opatření to má změnit? Proč Izrael a Spojené státy mění vyjednávací taktiku vůči Hamásu a může vést k odzbrojení tohoto teroristického hnutí?

Mobilní síť O2 se dopoledne potýkala s masivními výpadky. Jak odolná je infrastruktura mobilních síti v takových případech? Jaké finanční ztráty představuje pro stát nelegální zaměstnávání a jaké opatření to má změnit? Proč Izrael a Spojené státy mění vyjednávací taktiku vůči Hamásu a může vést k odzbrojení tohoto teroristického hnutí? Všechny díly podcastu Hlavní zprávy - rozhovory a komentáře můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Eighth Sunday after Pentecost August 3, 2025 Faith, Okemos Ecclesiastes 1:2, 12-14, 2:18-23, Psalm 49:1-12, Colossians 3:1-11, Luke 12:13-21   Living Under the Sun, Living from Above   Grace to you and peace… [Please take a few deep breaths. This will be a difficult sermon to hear, but I ask you to wait with me for the precious good news at the end…]   Vanity of vanities, says the Teacher, vanity of vanities! All is vanity… it is an unhappy business that God has given to human beings to be busy with.  I saw all the deeds that are done under the sun; and see, all is vanity and a chasing after the wind… What do mortals get from all the toil and strain with which we toil under the sun?  For all their days are full of pain, and their work is a vexation; even at night their minds do not rest. This also is vanity.  [There is nothing better for mortals than to eat and drink, and find enjoyment in their toil.  This also, I saw is from the hand of God…] Ecclesiastes 1:2, 12-14, 2:22-24   In an email sent from Kalea on Wednesday, I invited you to read the entire book of Ecclesiastes.  It is a sobering, largely dark assessment of the human story “under the sun.” If you had time to read it, I like to take a couple of minutes now to hear a sampling of your reactions…   I think of the tens of thousands in our country whose jobs have been either completely eliminated or made more burdensome.  I think of those trying to support themselves and/or their families but are paid far from sufficiently for their work, whose days, in the words of the Teacher, “are full of pain, and their work is a vexation.”   Maybe you, like me, remember projects in which you passionately spent countless hours and perhaps a fair amount of money, all to see them either immediately or eventually go up in smoke.  And don't we see in our own day the erosion of hard-fought protections for the poorest among us or for the people in Gaza or for the well-being of Earth itself?   I remember Dr. Leupold, an Old Testament professor at our seminary in Columbus, who reminded us of the importance of the phrase “under the sun.”  For him that was key to understanding the darkness and seemingly endless repetition, generation after generation, of the quest for power and the presence of insatiable greed.  [Historians don't have to look far to see the parallels of the rich getting richer and poor getting poorer throughout our 250 years as a nation and throughout the thousands of years of the lives and deaths of countless empires, nations, and kingdoms.]  So the perspective and wisdom of the Teacher in Ecclesiastes.   Which perspective is then enriched by Jesus' story of the rich man in our gospel for today. Jesus said:  Take care! Be on your guard against all kinds of greed; for one's life does not consist in the abundance of possessions.  For the rich man, life under the sun was going great.  And yet. as Jesus told them this story [here in the Message translation often read in our Tuesday Bible Studies]:  The farm of a certain rich man produced a terrific crop.  He talked to himself:  ‘What can I do? My barn isn't big enough for this harvest.'  Then he said, 'Here's what I'll do:  I'll tear down my barns and build bigger ones.  Then I'll gather in all my grain and goods, and I'll say to myself. “Self, you've done well!  You've got it made and can now retire.  Take it easy and have the time of your life!”  Just then God showed up and said, ‘Fool! Tonight you die.  And your barnful of goods – who gets it?'  That's what happens when you fill your barn with Self and not with God.”   Or this last thought in the words in the NRSV translation (in our bulletin):  So it is with those who store up treasures for themselves but are not rich toward God.   Next Sunday you will hear these further precious words of Jesus:  Do not be afraid, little flock, for it is your Father's good pleasure to give you the kingdom.  Sell your possessions, and give alms.  Make purses for yourselves that do not wear out, an unfailing treasure in heaven…  All of which is to say, in Jesus all is not vanity, all is not a chasing after the wind!   Which then takes us to our Second Reading from Colossians 3, words which call us to a live this vexing life above the sun.  These words in Colossians don't deny how hard and painful and empty and lonely and, yes, how finite is our life on Earth, our life under the sun.  The Teacher in Ecclesiastes counsels a little relief in seizing the moment [Carpe Diem] doing your best to find a measure of enjoyment in your work, in drink… in your eating…   But hear again these words:  Set your minds on things that are above, not on things that are on earth, for you have died, and your life is hidden with Christ in God.  When Christ who is your life is revealed, the you also will be revealed with him in glory.   What does that mean, “you have died”?  For me that means that in Jesus who died for me, my life is much more than my possessions, whether small or great, cheap or very expensive.  My life is not about fulfilling my bucket list before I die.  I have already died.   My eternal life with God and with all his children has already begun, made sure for us in the gift of holy baptism.  That's how powerful is his death on cross for me and for you and for all of creation.   So, the Teacher in writing the book of Ecclesiastes was only partly right.  Life is filled with vanity, [we might say ‘so full of s_t'].  But it is so much more than that. Hidden in the midst of our trials and tribulations, in our sorrows and in our fleeting happy moments with a drink and a little food to eat, is this gracious, wonderful gift of life from above.  Together with our siblings in Christ and with others of goodwill who do not yet recognize him as their Lord, we get to live an amazing life given to us from above.    For me that life is experienced in daily gratitude for the beauty of the Earth and for all who dwell therein.   I'm enriched these days by the sight of countless fields of corn and soybeans, of the gladiolas in our backyard, of the swaying trees, taking in tons of excess CO2 and giving back an abundance of O2.  And I think of countless very real people, including you all, who enrich my life and lift me up when I get down or hyper-critical or self-centered, when I'm like the rich man who thought only about himself.   But when our old under-the-sun-self seeks to smother our gratitude for this life from above, when that self tries to make us forget the grace-filled eternal life that Jesus won for us, the Holy Spirit, who may be especially present in the moments we need to take for quiet reflection, will prompt us to put to death that old self filled with greed and lies and malice and abusive language.  Martin Luther called it “daily dying” a needful daily discipline putting to death our old self and receiving the precious gift of a new, risen life from above, putting on the clothing of compassion, kindness, humility, quiet strength, and patience.   I invite you to repeat after me: In Jesus' name I put to death my old self And, in Jesus' name, with a grateful heart, I receive today a new, risen life.   Amen.                                                                     

Stand-up comedian and comedy writer, Phil Wang joins us on the podcast to discuss his relationship with The Beatles. Phil tells us of his memories growing up listening to the band in a Beatles-obsessed household in Borneo, his unusual teenage music tastes, and taking his Dad to see Macca at the O2. This week's subscriber-only feature Pick A Song sees us dive into The White Album's Sexy Sadie. Get access by subscribing on Patreon or Apple Podcasts. Links of Note:Wang in There, Baby: https://www.netflix.com/gb/title/81720942Patreon: https://patreon.com/personalbeatles Hosted on Acast. See acast.com/privacy for more information.

This episode we are joined by Olivier Award nominated actor, writer and performer Rob Madge!  Rob is currently starring at the Emcee in West End's Cabaret at The Kit Kat Club and is also known for their one person show, My Son's a Queer (But What Can You Do?).  Their other credits include Mary Poppins, the 25th Anniversary Concert of Les Miserables at the O2, Buyer & Celler, and has performed at the London Palladium for their Christmas Pantomime shows since 2022. They return this year as The Diva or Dreams in Sleeping Beauty. They are currently working on an adaptation of Charley's Aunt playing at Watermill Theatre this fall! And they are working on a new musical set to come out next year!We talk with Rob about their experience bringing My Son's a Queer to New York, their hopes of doing Shakespeare, truly knowing that musical theater was what they were meant to do and much more!

Bret McKenzie now mainly works on movie soundtracks, the Simpsons, Minecraft and the Muppets among them, which brings the pure delight of hearing his songs sung by Lady Gaga, Benedict Cumberbatch, Miss Piggy and Tony Bennett. He talks here about his early life in Wellington (ballet teacher Mum, racehorse trainer Dad), narrative comedy, songwriting heroes and his new album Freak Out City, and unravels New Zealand's double-edged sense of humour. Along with … … how Randy Newman pitches songs for soundtracks … “the test of a good song works is if it works with just one instrument” … lyrics he loved growing up like 16 Tons by Tennessee Ernie Ford – ‘Some people say a man is made out of mud/ A poor man's made out of muscle and blood' … Morrissey's wounded reaction to his sausage-firing Quilloughby on the Simpsons ‘Panic On The Streets Of Springfield' ... solving the “fun puzzles” of a song brief and writing for “donkeys who have a dream” … the ingenious humour of John Prine, Harry Nilsson and Leonard Cohen … the moment in his live shows where he asks the audience for a story and creates a song around it – “one woman suggested ‘falling out of love' with her husband standing right beside her” ... playing the local girls schools aged 15 as the drummer in a James Brown funk band … reworking rejected songs – “which was hard with one from Paddington with its multiple rhymes for marmalade and Peru” … Flight Of The Conchords lampooning the acts they loved (Bowie, Pet Shop Boys) and playing the O2 – “pretending to be a stadium band and the audience pretending to be a stadium audience” … live on-stage application of the John Lennon “pomegranate” lyric-solving technique … “Play like a used car salesman! I need a Steely Dan solo here!” Recording with LA session legends like Leland Sklar. Order Bret's ‘Freak Out City' album here: https://music.subpop.com/bretmckenzie_freakoutcityFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Tour dates and tickets …https://www.ticketmaster.co.uk/bret-mckenzie-tickets/artist/5380913 Hosted on Acast. See acast.com/privacy for more information.

Bret McKenzie now mainly works on movie soundtracks, the Simpsons, Minecraft and the Muppets among them, which brings the pure delight of hearing his songs sung by Lady Gaga, Benedict Cumberbatch, Miss Piggy and Tony Bennett. He talks here about his early life in Wellington (ballet teacher Mum, racehorse trainer Dad), narrative comedy, songwriting heroes and his new album Freak Out City, and unravels New Zealand's double-edged sense of humour. Along with … … how Randy Newman pitches songs for soundtracks … “the test of a good song works is if it works with just one instrument” … lyrics he loved growing up like 16 Tons by Tennessee Ernie Ford – ‘Some people say a man is made out of mud/ A poor man's made out of muscle and blood' … Morrissey's wounded reaction to his sausage-firing Quilloughby on the Simpsons ‘Panic On The Streets Of Springfield' ... solving the “fun puzzles” of a song brief and writing for “donkeys who have a dream” … the ingenious humour of John Prine, Harry Nilsson and Leonard Cohen … the moment in his live shows where he asks the audience for a story and creates a song around it – “one woman suggested ‘falling out of love' with her husband standing right beside her” ... playing the local girls schools aged 15 as the drummer in a James Brown funk band … reworking rejected songs – “which was hard with one from Paddington with its multiple rhymes for marmalade and Peru” … Flight Of The Conchords lampooning the acts they loved (Bowie, Pet Shop Boys) and playing the O2 – “pretending to be a stadium band and the audience pretending to be a stadium audience” … live on-stage application of the John Lennon “pomegranate” lyric-solving technique … “Play like a used car salesman! I need a Steely Dan solo here!” Recording with LA session legends like Leland Sklar. Order Bret's ‘Freak Out City' album here: https://music.subpop.com/bretmckenzie_freakoutcityFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Tour dates and tickets …https://www.ticketmaster.co.uk/bret-mckenzie-tickets/artist/5380913 Hosted on Acast. See acast.com/privacy for more information.

Bret McKenzie now mainly works on movie soundtracks, the Simpsons, Minecraft and the Muppets among them, which brings the pure delight of hearing his songs sung by Lady Gaga, Benedict Cumberbatch, Miss Piggy and Tony Bennett. He talks here about his early life in Wellington (ballet teacher Mum, racehorse trainer Dad), narrative comedy, songwriting heroes and his new album Freak Out City, and unravels New Zealand's double-edged sense of humour. Along with … … how Randy Newman pitches songs for soundtracks … “the test of a good song works is if it works with just one instrument” … lyrics he loved growing up like 16 Tons by Tennessee Ernie Ford – ‘Some people say a man is made out of mud/ A poor man's made out of muscle and blood' … Morrissey's wounded reaction to his sausage-firing Quilloughby on the Simpsons ‘Panic On The Streets Of Springfield' ... solving the “fun puzzles” of a song brief and writing for “donkeys who have a dream” … the ingenious humour of John Prine, Harry Nilsson and Leonard Cohen … the moment in his live shows where he asks the audience for a story and creates a song around it – “one woman suggested ‘falling out of love' with her husband standing right beside her” ... playing the local girls schools aged 15 as the drummer in a James Brown funk band … reworking rejected songs – “which was hard with one from Paddington with its multiple rhymes for marmalade and Peru” … Flight Of The Conchords lampooning the acts they loved (Bowie, Pet Shop Boys) and playing the O2 – “pretending to be a stadium band and the audience pretending to be a stadium audience” … live on-stage application of the John Lennon “pomegranate” lyric-solving technique … “Play like a used car salesman! I need a Steely Dan solo here!” Recording with LA session legends like Leland Sklar. Order Bret's ‘Freak Out City' album here: https://music.subpop.com/bretmckenzie_freakoutcityFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Tour dates and tickets …https://www.ticketmaster.co.uk/bret-mckenzie-tickets/artist/5380913 Hosted on Acast. See acast.com/privacy for more information.

Delayed (AKA deferred) Cord Clamping (DCC) is extremely beneficial for both the preterm and term neonate. In September 2025, a new Clinical Practice Update (CPU) will be released by the ACOG regarding the amount of time DCC should be done for preterm newborns. This updates data from a Clinical Expert Series which was released in 2022, called “Management of Placental Transfusion to the Neonate”. Is the recommended amount of DCC 30 sec, 45 sec, or at least 60 seconds for preterm newborns? We will highlight this data in this episode. PLUS, we will very quickly summarize a separate yet related publication from JAMA Pediatrics regarding the use of supplemental O2 (100% PP face mask) during DCC for babies born at 22- 28 weeks. Listen in for details.1. ACOG CPU, Sept 2025: “An Update to Clinical Guidance for Delayed UmbilicalCord Clamping After Birth in Preterm Neonates”2. ACOG Clinical Expert Series, Management of Placental Transfusion to the Neonate”; 2022. 3. JAMA PEDIATRICS (July 21, 2025): https://jamanetwork.com/journals/jamapediatrics/article-abstract/2836681

Is democracy failing because citizens aren't truly thinking through the issues?In this episode, we hear from Prof. James Fishkin, Stanford scholar and creator of Deliberative Polling, a groundbreaking method used around the world to reveal what people would think if they had the chance to deliberate in depth.Fishkin explains why deliberation is about more than civil conversation. It's about helping ordinary people make better decisions on complex policy questions. Discover how projects like America in One Room prove citizens can engage thoughtfully, bridge divides, and shape smarter policies.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

On this episode of Happy Hour with Bundle Birth Nurses, Heidi joins Sarah Lavonne and Justine to explore the fetal monitoring strip from the baby's perspective and physiology! They reveal how fetal hemoglobin, baroreceptors and chemoreceptors, autonomic tug-of-war, and stress hormones power a baby's built-in defense system during labor. They talk about why low O2 saturations are normal, what truly triggers variables and lates, and tips to prep for C-EFM certification.  Thanks for listening and subscribing!Send in your question to be featured in Season 7 of the Pod! (90 sec total)https://www.speakpipe.com/HappyHourwithBundleBirthNurses Helpful Links! C-EFM Exam Prep Class OB Emergency Pocket GuideBasic Fetal Monitoring ClassPhysiologic Coping classShifting the Pitocin Paradigm ClassNCC C-EFM Exam 

For over 40 years, Helena Bonham Carter has delighted us with roles including Lucy Honeychurch in Room with a View, Princess Margaret in The Crown and Harry Potter's much-loved villain, Bellatrix Lestrange. She joined Nuala McGovern to discuss her latest role in new film, Four Letters of Love, based on the bestselling book of the same name. Eight babies have been born in the UK using genetic material from three people to prevent devastating and often fatal conditions. The method, pioneered by UK scientists, combines the egg and sperm from a mum and dad with a second egg from a donor woman. The technique has been legal in the UK for a decade but this is the first proof it is leading to children born free of incurable mitochondrial disease, which is normally passed from mother to child. Anita Rani was joined by Kat Kitto who has two daughters, one of whom has mitochondrial disease, and Louise Hyslop, consultant embryologist at the Newcastle Fertility Centre to discuss.A new report by London's Victims' Commissioner, Claire Waxman, says that victims are being forced to quit the criminal justice system in huge numbers amid record court delays and traumatic process. She joined Nuala to explain why they are saying 'there is a near total failure in seeing offenders brought to justice', especially when it comes to female victims of violence. In the second part of our series about women and gaming, we find out more about the impact gaming can have on women's lives. Nuala heads to the Virgin Media Gamepad at the O2 to meet some of the women from the Black Girl Gamers community, who have over 10,000 members around the world. The bestselling author Louise Candlish joined Anita to talk about her latest novel - A Neighbour's Guide to Murder - which explores the practice of sex for rent and a trial by social media. The American jazz singer Samara Joy has five Grammy awards to her name and is quickly gaining superstar status in the jazz world. She is making her debut at the BBC Proms tonight, where she will be backed by the BBC Concert Orchestra, in a special tribute to the Great American Songbook. The Prom will be also be live on Radio 3, on BBC Four and iPlayer.Presenter: Anita Rani Producer: Annette Wells Editor: Deiniol Buxton

War, political chaos, economic fears, AI disruption—the world feels like it's on fire. And the media? It never stops pouring fuel on the flames.In this final chapter of the Outrage on the Mic series, we explores how outrage has become the currency of media—from the fiery sermons of Father Coughlin to the viral rants of today's podcasters and political pundits.Why does outrage work so well? Can creators build something different in a world addicted to anger and fear? And what does it look like to choose nuance over noise—even when it costs you clicks?Hear from voices who are resisting the outrage machine and learn why rage sells…but we don't have to buy it.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

Our guest for this week is Sara Olson.  Sara (her TikTok name is SKEEETAH) is from the Wolf River area of Wisconsin which just happens to hold the highest concentration of the fungus that causes Blastomycosis. When Sara got Blastomycosis in January 2024, she thought it was 'just the flu'.  With a chest xray, she was diagnosed with pneumonia.  Several rounds of antibiotics didn't help so she did a CT scan where they found an embolism.  Still not knowing anything else, they continued treating her for bacterial pneumonia.  They did a swab of her sputum in which her health providers found no bacterial growth, but there was fungal growth.  "For some reason they didn't do fungal testing" she was admitted, released and readmitted all the while she was being treated for bacterial pneumonia.  The final hospitalization had her O2 levels drop to 30 and she was intubated, her family was called to come and say their goodbyes...  You'll have to listen to the interview to learn more.  She is lucky to be alive! Blastomycosis is a fungal infection and was linked to the Little Wolf River in Waupaca County, Wisconsin, during a summer 2015 outbreak.  People who went tubing on the river were exposed to the fungus, with 59 confirmed and 39 probable cases reported according to the Wisconsin Department of Health Services (W-DHS). The fungus, Blastomyces, lives in soil and decaying organic matter, and its spores can become airborne when disturbed. Inhaling these spores can cause blastomycosis, a disease primarily affecting the lungs, though it can spread to other parts of the body. While most blastomycosis cases are sporadic, this outbreak highlighted the need for awareness about this preventable cause of illness.    Key Details about the Outbreak: Cause: The outbreak was attributed to the fungus Blastomyces, which is commonly found in soil and decaying matter.    Exposure: People who participated in river tubing on the Little Wolf River were exposed to the fungus.    Symptoms: Blastomycosis can cause flu-like symptoms, such as fever, cough, muscle aches, and fatigue, but it can also lead to serious health problems if not treated.    Transmission: The infection is not spread from person to person.    Treatment: Blastomycosis can be treated with antifungal medications.    Outbreak Scale: This outbreak was one of the largest in recent Wisconsin history, with 59 confirmed and 39 probable cases.    Prevention: Awareness of the potential for infection is key, especially in areas where the fungus is known to be present.    Additional Information: Endemic Area: Blastomycosis is endemic in the Ohio and Mississippi River valleys, the Great Lakes region, and the southeastern United States according to the CDC.    Symptoms: Common symptoms include cough, fever, chest pain, fatigue, and skin sores.    Risk Factors: Individuals with weakened immune systems or chronic illnesses may be more susceptible to severe illness.    Not Limited to the Wolf River: While the Little Wolf River outbreak was significant, blastomycosis can occur in other areas with suitable environmental conditions.  Blastomyces lives in moist soil in parts of North America. It's too small to see, so you can breathe it into your lungs without knowing it. There, it can grow and make you sick. It sometimes spreads to your skin or other parts of your body. It's hard to avoid breathing in Blastomyces fungus if you live in an area where it's common. While not entirely preventable, there are some steps you can take to reduce your risk of blastomycosis: Avoid disturbing large areas of dirt and dust, especially in areas near water. If your job or hobbies expose you to soil that's likely to contain Blastomyces, wear an N95 (or KN95) respirator mask to help filter the air you breathe.  

In Part 2 of our special series Outrage on the Mic, we go back in time to explore how public outrage has shaped societies long before the digital age. David Beckemeyer is joined by Outrageous History! host Ernest Granson, who brings his journalist's eye to scandals, uprisings, and media-fueled conflicts from the French Revolution to the Spanish-American War.Whether you're a history nerd, media critic, or just trying to make sense of today's outrage culture, this episode is for you.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

RE-RELEASE This was first published in 2023 but it's so good we are running it back! Buckle up, PGY-1's! Intern year is starting whether you're ready or not. Don't fret, BTK has your back to make sure you dominate the first year of residency. Today, we're hitting the wards and tackling some of the scary clinical scenarios you will see as an intern. Hosts: Shanaz Hossain, Nina Clark Tips for new interns: THINGS TO REMEMBER ·       BREATHE. In most cases, you have a little bit of time – at least enough to take a breath and calm down outside the room before heading into an emergency. Panic doesn't help anybody. ·       See the patient. Getting a bunch of pages? Worried about someone? Confused as to what's going on? Go see the patient and chat with the bedside team. ·       Know your toolbox. There are a ton of people around who can help you in the hospital, and knowing the basic labs/imaging studies and when to use them can help you to triage even the sickest patients. ·       Load the boat. You've heard this one from us all week! Loop senior level residents in early. HYPOTENSION ·       Differential: measurement error, patient's baseline, and don't miss – SHOCK.            - Etiologies of shock: hemorrhagic, hypovolemic, ·       On the phone: full set of vitals, accurate I/Os, ·       On the way: recent notes, PMH/PSH including from this hospital stay, and vitals/I&Os/studies from earlier in the day ·       In the room: ABCDs – rapidly gives you a sense of how high acuity the patient is ·       Get more info: labs, consider imaging, work up specific types of shock based on clinical concern. ·       Initial management: depends on etiology of hypotension; don't forget to consider peripheral or central access, foley catheterization for close monitoring of urine output, and level of care HYPOXEMIA ·       Differential: atelectasis, baseline pulmonary disease, pneumonia, PE, hemo/pneumothorax, volume overload ·       On the phone: full set of vitals, amount of supplemental oxygen required and delivery device, rate of escalation in oxygen requirement ·       On the way: review PMH/PSH, known injuries (known hemothorax/pneumothorax? Rib fractures? Chest tubes in already?), risk factors for DVT/PE, review I/Os for evidence of volume status, vitals and labs for evidence of infection ·       In the room: ABCDs, pulmonary and cardiac exam, volume status exam ·       Get more info: basic labs, ABG if worried about oxygenation, CXR, consider bedside US of the lungs/heart, if high suspicion for PE consider CTA chest ·       Initial Management: supplemental O2, higher level of care, consider intubation or other supplemental oxygenation adjuncts, additional management dependent on suspected etiology ·       ABG Vs VBG (IBCC): https://emcrit.org/ibcc/vbg/ ALTERED MENTAL STATUS ·       Differential: stroke, medication effect, hypoxemia or hypercarbia, toxic or medication effect, endocrine/metabolic, stroke or MI, psychiatric illness, or infections, delirium ·       On the way: review PMH/PSH, recent notes for evidence of altered mentation or agitation, or signs hinting at above etiologies ·       In the room: ABCDs, focal neuro deficits?, alert/oriented? Be sure the patient's mental status is adequate for airway protection! ·       Get more info: basic labs, blood gas/lactate, CT head noncontrast if concerned for stroke. ·       Initial management: rule out above; if concerned about delirium, optimize sleep/wake cycles, pain control, and lines/drains/tubes. OLIGURIA ·       Differential: prerenal due to hypovolemia or low effective circulating volume, intrinsic renal disease, post-renal obstruction ·       On the phone: clarify functional foley or bladder scan results, full set of vitals ·       On the way: review PMH/PSH, known injuries (known hemothorax/pneumothorax? Rib fractures? Chest tubes in already?), risk factors for DVT/PE, review I/Os for evidence of volume status, vitals and labs for evidence of infection ·       In the room: ABCDs, confirm functioning foley catheter ·       Get more info: basic labs, urine electrolytes, consider fluid challenge to evaluate responsiveness, consider adjuncts including renal US ·       Initial management: typically consider IVF bolus initially, but if patient not volume responsive, don't overload them -- look for other etiologies! TACHYCARDIA ·       Differential: sinus tachycardia (pain, hypovolemia, agitation, infection), cardiac arrhythmia, MI, PE ·       On the phone: full set of vitals, acuity of change in heart rate, updated I/Os ·       On the way: Review PMH/PSH, known cardiac history, cardiac and PE risk factors, volume resuscitation, signs concerning for infection, updated I/Os ·       In the room: ABCDs, cardiac/pulmonary exam, evaluate for any localizing signs for infection ·       Get more info: basic labs, EKG, consider CXR, troponins ·       Initial management: depends heavily on etiology Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our new how-to video series on suture and knot-tying skills – https://behindtheknife.org/video-playlists/btk-suture-practice-kit-knot-tying-simulator-how-to-videos/

O2 shows us why Bill Maher is wrong about kids. Plus our recommendations for summer books about friendship.   Follow Childish: twitter.com/childishpod instagram.com/childishpod Follow Greg: twitter.com/GregFitzShow instagram.com/gregfitzsimmons Follow Alison: twitter.com/AlisonRosen instagram.com/alisonrosen

Outrage Overload x Outrage FactoryThis week, we kick off our special July series, Outrage on the Mic, with a fun and irreverent crossover featuring the hosts of Outrage Factory—Dale Deruiter and Geoff Gauthier.We explore the absurdity of online outrage, how humor can both defuse and amplify it, and what it means to build a show around the week's most ridiculous controversies.This is Part 1 of our Outrage on the Mic series, where we partner with fellow podcasters to explore how different voices and formats tackle outrage culture. ➡️ Part 2 drops July 9 with Outrageous History ➡️ Part 3 lands July 16 with a special reflection on “rage-as-a-growth-strategy” in media

Our primary focus immediately following return of spontaneous circulation (ROSC) is aimed at ensuring adequate perfusion of the patient's vital organs and decreasing cerebral damage.Post-arrest goals for O2 saturation, ETCO2, and BP/MAP.Indications for use of an antiarrhythmic after ROSC.Determining which antiarrhythmic to use post cardiac arrest. Administration of Amiodarone or Lidocaine to control ventricular ectopy after ROSC.The use of Amiodarone post arrest if no antiarrhythmics were administered prior to obtaining ROSC.Links to other medical podcasts that cover antiarrhythmics and other ACLS-related topics are on the Pod Resource page at PassACLS.com.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

From intimate stories about his father's songwriting contributions to Led Zeppelin to candid revelations about the O2 reunion show, Jason Bonham opens up about his musical journey. He discusses the challenges and joys of performing Physical Graffiti in its entirety, shares touching moments about documenting shows for his granddaughter, and reveals previously untold stories about the legendary band's creative process. Also on the podcast, Dean DeLeo opens up about his musical evolution from STP to crafting new sounds with One More Satellite. He shares personal insights about family collaborations and finding inspiration in unexpected places. Catch Eddie Trunk every M-F from 3:00-5:00pm ET on Trunk Nation on SiriusXM Faction Talk Channel 103.And don't forget to follow Eddie on Twitter and Instagram!Follow the link to get your free 3-month trial of SiriusXM: http://siriusxm.com/eddietrunk Find all episodes of Trunk Nation: https://siriusxm.com/trunknation

Why is it so hard to have civil conversations about the Israeli-Palestinian conflict? And can we break through the outrage culture, media tribalism, and polarization that dominate today's discourse?In this episode, we talk with Adam Boaz Becker, founder of Headon.AI, an AI platform designed to foster political dialogue and bridge divides. Adam shares what he's learned from years of street interviews in Israel and the West Bank, the challenges of creating conversations in conflict zones, and how social media and traditional media often make things worse.We also explore how AI might help us talk across divides, and why simply seeking common ground might not be the solution—sometimes, peaceful coexistence is powerful enough.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.